A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)

Sponsor: Novartis.

The goal of this  trial is to provide evidence on the effects of inclisiran versus placebo on cardiovascular events in participants with established atherosclerotic cardiovascular disease who have elevated LDL-C leverl despite being on a high-intensity statin.

Study Team:
Project Manager: A. Branderhorst
Sub investigator: J.  Tiebesl, K. Ricken

People involved